Amer Zeidan: Reducing Clinical Trial Eligibility Barriers for Myelodysplastic Syndromes/Neoplasms
Amer Zeidan, Associate Professor of Medicine (Hematology) at Yale University, shared a post on X, about a paper by him and colleagues, published in The Lancet Hematology.
“Kicking off 2025 with this outstanding International Consortium for MDS (icMDS) first online Blood Journal effort that every clinical researcher, regulator, industry sponsor, reviewer, or anyone involved in MDSsm clinical trials should read before writing or approving an MDSsm clinical trial protocol.”
Led by Uma Borate, the International Consortium for MDS (icMDS) shows eligibility criteria for lower/higher risk MDSsm often do not vary across trial phases or reflect known drug safety signals. We recommend inclusive, phase- and drug-specific eligibility to enhance trial access and applicability to the world.
This work follows our recent international, data-driven approach to harmonization of MDSsm classification schema which would also improve the consistency of trial eligibility.
This effort also follows a seminal consensus report developed by the IWG group and endorsed by the International Consortium for MDS (icMDS) of IWG2023 response criteria for higher risk MDSsm which improved clinical trial result reporting to be more patient-centric and consistent, and are already widely accepted and used.”
More posts featuring Amer Zeidan.
Amer Zeidan is an Associate Professor of Medicine (Hematology) at Yale University. He is also the medical director of Hematology Early Therapeutics Research, the leader of the Myeloid Malignancies DART (Disease Aligned Research Team), and the director of Continuing Medical Education (CME) at the Hematology division and chairs the Protocol Review Committee (PRC) at Yale Cancer Center. Dr. Zeidan is a well-known leukemia researcher with a special focus on targeted therapies and immunotherapy for myeloid malignancies, and a social media influencer in the field of blood cancer.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023